Bayer (FRA:BAYN) Stock Price Crosses Above 200-Day Moving Average of $62.34

Bayer AG (FRA:BAYN)’s share price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $62.34 and traded as high as $69.42. Bayer shares last traded at $69.32, with a volume of 2,439,508 shares changing hands.

Several equities analysts have recently commented on the company. Morgan Stanley set a €86.00 ($100.00) price objective on Bayer and gave the company a “buy” rating in a research report on Tuesday, November 12th. HSBC set a €63.00 ($73.26) price objective on Bayer and gave the company a “neutral” rating in a research report on Wednesday, November 27th. DZ Bank reiterated a “neutral” rating on shares of Bayer in a research report on Thursday, October 31st. Barclays set a €85.00 ($98.84) price objective on Bayer and gave the company a “buy” rating in a research report on Friday, October 25th. Finally, Deutsche Bank set a €70.00 ($81.40) price objective on Bayer and gave the company a “neutral” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of €78.47 ($91.24).

The firm has a 50-day moving average of €68.52 and a 200-day moving average of €62.34.

Bayer Company Profile (FRA:BAYN)

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: Technical Analysis

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.